Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
Civic Science on MSN4d
For Most GLP-1 Users, Taking Prescription Weight-Loss Drugs Comes With a Social StigmaThis is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The ...
those with a prescription for drugs like Ozempic (semaglutide) or Saxenda (liraglutide) had a 40 per cent lower rate of ...
A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show ... was shocked to find out that the company’s prescription drug costs had soared ...
Ozempic, a diabetes medication by Novo Nordisk, has gained popularity for its weight loss effects, sparking debate.
But how exactly do weight loss drugs really work for individual women ... Here, our roundup of everyday women and their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback